Want to see BDRX full AI Analyst Report?
BDRX Stock Chart & Stats
$0.87
-$0.08(-4.85%)
At close: 4:00 PM EDT
$0.87
-$0.08(-4.85%)
Day’s Range― - ―
52-Week Range$0.51 - $59.40
Previous Close$1.75
Volume25.39K
Average Volume (3M)7.15M
Market Cap
$612.40K
Enterprise Value$21.72B
Total Cash (Recent Filing)$3.21M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Apr 23, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-50.00
Shares Outstanding1,029,066
10 Day Avg. Volume195,495
30 Day Avg. Volume7,148,561
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.02
Price to Sales (P/S)0.00
P/FCF Ratio-0.03
Enterprise Value/Market Cap35.46K
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-167.98K
Enterprise Value/Ebitda-4.64K
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)$7.66K
Bulls Say, Bears Say
Bulls Say
Low Leverage And Stronger Asset BaseVery low debt and higher equity and assets provide a stronger financial base for funding clinical work than a highly leveraged structure. This reduces interest-related pressure and preserves flexibility, although ongoing losses still mean the balance sheet must be managed carefully.
Progress In Late-stage Oncology DevelopmentExpansion into Canada and enrollment of 92 of 168 planned subjects show the registrational program is progressing beyond early planning. Continued execution could improve the pipeline’s development value and create a clearer path toward potential approval in a defined oncology indication.
Immediate Liquidity From Warrant ExerciseThe $2.3 million warrant exercise supplies immediate gross cash and strengthens near-term liquidity while programs advance. This can help sustain operations and clinical execution over coming months, although the accompanying warrants create a future equity burden.
Bears Say
No Commercial Revenue And Continuing LossesZero revenue in both 2024 and 2025 confirms the company remains pre-commercial, while operating and net losses show no established product economics. Without recurring sales, funding clinical development depends on external capital or eventual partnering and commercialization.
Capital-intensive Development And Cash BurnOperating cash use reached £4.61 million in 1H26 and R&D spending rose to £2.92 million as Serenta and MTX240 work accelerated. This capital intensity means cash consumption is likely to remain material while programs advance, increasing the need for repeated financing.
Potential Dilution From Expanded Equity CapacityThe new Series P warrants cover up to 4,408,436 ADSs, and shareholders authorized up to £25 million of future share issuance. These tools improve funding access but can materially expand the equity base, diluting existing holders as clinical spending continues.
Biodexa Pharmaceuticals News
BDRX FAQ
What was Biodexa Pharmaceuticals’s price range in the past 12 months?
Biodexa Pharmaceuticals lowest stock price was $0.51 and its highest was $59.40 in the past 12 months.
What is Biodexa Pharmaceuticals’s market cap?
Biodexa Pharmaceuticals’s market cap is $612.40K.
When is Biodexa Pharmaceuticals’s upcoming earnings report date?
Biodexa Pharmaceuticals’s upcoming earnings report date is Apr 23, 2027 which is in 196 days.
How were Biodexa Pharmaceuticals’s earnings last quarter?
Biodexa Pharmaceuticals released its earnings results on Sep 11, 2026. The company reported $0 earnings per share for the quarter.
Is Biodexa Pharmaceuticals overvalued?
According to Wall Street analysts Biodexa Pharmaceuticals’s price is currently Overvalued.
Does Biodexa Pharmaceuticals pay dividends?
Biodexa Pharmaceuticals does not currently pay dividends.
What is Biodexa Pharmaceuticals’s EPS estimate?
Biodexa Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biodexa Pharmaceuticals have?
Biodexa Pharmaceuticals has 1,029,066 shares outstanding.
What happened to Biodexa Pharmaceuticals’s price movement after its last earnings report?
Biodexa Pharmaceuticals reported an EPS of $0 in its last earnings report. Following the earnings report the stock price went down -13.846%.
Which hedge fund is a major shareholder of Biodexa Pharmaceuticals?
Currently, no hedge funds are holding shares in BDRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biodexa Pharmaceuticals
Biodexa Pharmaceuticals Plc, a biopharmaceutical company in the clinical development stage, is dedicated to advancing a diverse portfolio of products. Founded in 2000 and headquartered in Cardiff, United Kingdom, the company was formerly known as Midatech Pharma plc until its rebranding in March 2023. Its research and development efforts are focused on addressing significant unmet medical needs, including familial adenomatous polyposis, non-muscle invasive bladder cancer, Type 1 diabetes, and a spectrum of rare or orphan brain cancers. The company's primary drug candidate, Tolimidone, a selective activator of the lyn kinase enzyme, is currently undergoing Phase II clinical trials for the management of Type 1 diabetes. Additionally, Biodexa is progressing MTX110 through Phase I studies as an investigational treatment targeting specific challenging brain malignancies such as diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. Beyond its direct drug pipeline, Biodexa Pharmaceuticals also provides a suite of advanced drug delivery platforms designed to optimize therapeutic efficacy. These include Q-Sphera, a microtechnology utilizing polymer microspheres for controlled, sustained release of medications; MidaSolve, an oligosaccharide nanotechnology that facilitates the solubilization of drugs, enabling their direct and localized administration into tumor sites; and MidaCore, which employs gold nanoparticles for precise targeting of diseased areas, allowing for the delivery of either chemotherapeutic or immunotherapeutic agents. The company has established strategic collaboration agreements with pharmaceutical industry leaders Janssen and Melior.
Technical Analysis
―
Indaptus Therapeutics
―
InMed Pharmaceuticals
―
Enveric Biosciences
―
CNS Pharmaceuticals
―
Ownership Overview
―
Insiders
―
Mutual Funds
1.49% Other Institutional Investors
98.51% Public Companies and
Individual Investors